{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T04:21:11Z","timestamp":1795148471046,"version":"4.10.3"},"reference-count":37,"publisher":"Elsevier BV","issue":"10466","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/s0140-6736(24)01774-4","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T18:32:30Z","timestamp":1731609150000},"page":"1940-1954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":200,"title":["Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial"],"prefix":"10.1016","volume":"404","author":[{"given":"Jeremy S","family":"Abramson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hertzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Qiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifaa","family":"Abdulhaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Herbaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan M","family":"Zaucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Yoon","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Ghesquieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Simko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Orellana-Noia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Relf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Kallemeijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefania","family":"Mulvihill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth P","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(24)01774-4_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ajh.26151","article-title":"2021 Update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management","volume":"96","author":"Susanibar-Adaniya","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/S0140-6736(24)01774-4_bib2","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bjh.15412","article-title":"How I manage patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"182","author":"Gisselbrecht","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/S0140-6736(24)01774-4_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(24)01774-4_bib4","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(24)01774-4_bib5","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(24)01774-4_bib6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(24)01774-4_bib7","first-page":"163","article-title":"Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharmaceut Med"},{"key":"10.1016\/S0140-6736(24)01774-4_bib8","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1182\/bloodadvances.2020002118","article-title":"Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies","volume":"4","author":"Sermer","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/S0140-6736(24)01774-4_bib9","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S0140-6736(24)01774-4_bib10","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/S0140-6736(24)01774-4_bib11","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2022-157554","article-title":"Relapse is uncommon in patients with large B-cell lymphoma who are in complete remission at the end of fixed-course glofitamab treatment","volume":"140","author":"Hutchings","year":"2022","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(24)01774-4_bib12","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1080\/10428194.2021.1901090","article-title":"Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory\/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation","volume":"62","author":"Cazelles","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/S0140-6736(24)01774-4_bib13","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/annonc\/mdm133","article-title":"Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy","volume":"18","author":"El Gnaoui","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/S0140-6736(24)01774-4_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1600-0609.2007.00996.x","article-title":"GEMOX-R regimen is a highly effective salvage regimen in patients with refractory\/relapsing diffuse large-cell lymphoma: a phase II study","volume":"80","author":"L\u00f3pez","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/S0140-6736(24)01774-4_bib15","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3324\/haematol.2013.090597","article-title":"Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial","volume":"98","author":"Mounier","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/S0140-6736(24)01774-4_bib16","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1172\/JCI43656","article-title":"Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice","volume":"121","author":"Lesterhuis","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/S0140-6736(24)01774-4_bib17","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.4049\/jimmunol.170.10.4905","article-title":"Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells","volume":"170","author":"Nowak","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/S0140-6736(24)01774-4_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/sj.bjc.6605465","article-title":"Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses","volume":"102","author":"Liu","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/S0140-6736(24)01774-4_bib19","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1158\/0008-5472.CAN-10-2670","article-title":"Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice","volume":"71","author":"Mundy-Bosse","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/S0140-6736(24)01774-4_bib20","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/cas.12918","article-title":"Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation","volume":"107","author":"Hayashi","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/S0140-6736(24)01774-4_bib21","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(24)01774-4_bib22","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/S0140-6736(24)01774-4_bib23","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/S0140-6736(24)01774-4_bib24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(24)01774-4_bib25","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2376.2376","article-title":"Validation of the functional assessment of cancer therapy-lymphoma (FACT-Lym) in patients with relapsed\/refractory mantle cell lymphoma","volume":"112","author":"Carter","year":"2008","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(24)01774-4_bib26","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/147176","article-title":"The development and validation of a measure of health-related quality of life for non-Hodgkin's lymphoma: the Functional Assessment of Cancer Therapy\u2014Lymphoma (FACT-Lym)","volume":"2013","author":"Hlubocky","year":"2013","journal-title":"Lymphoma"},{"key":"10.1016\/S0140-6736(24)01774-4_bib27","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/S0140-6736(24)01774-4_bib28","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data","volume":"6","author":"Sehn","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/S0140-6736(24)01774-4_bib29","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3324\/haematol.2023.283480","article-title":"Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study","volume":"109","author":"Duell","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/S0140-6736(24)01774-4_bib30","first-page":"1184","article-title":"Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study","volume":"109","author":"Caimi","year":"2024","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.1016\/S0140-6736(24)01774-4_bib31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood-2023-172951","article-title":"R-GemOx plus nivolumab vs R-GemOx as second-line therapy for large B-cell lymphoma in transplant-ineligible patients: interim analysis of the Niveau trial, an international, randomized phase 3 study of the AGMT, GLA, HOVON, Lysa and PLRG","volume":"142","author":"Held","year":"2023","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(24)01774-4_bib32","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1038\/s41591-023-02572-5","article-title":"Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial","volume":"29","author":"Houot","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/S0140-6736(24)01774-4_bib33","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/S0140-6736(24)01774-4_bib34","series-title":"Side effects of drugs annual","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/bs.seda.2018.08.012","article-title":"Chapter 45 - cytostatic agents","author":"Keshishyan","year":"2018"},{"key":"10.1016\/S0140-6736(24)01774-4_bib35","series-title":"Oxaliplatin","author":"Devanabanda","year":"2024"},{"key":"10.1016\/S0140-6736(24)01774-4_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101939","article-title":"Nirmatrelvir\/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry","volume":"58","author":"Salmanton-Garc\u00eda","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/S0140-6736(24)01774-4_bib37","first-page":"1269","article-title":"Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma","volume":"109","author":"Song","year":"2024","journal-title":"Haematologica"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673624017744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673624017744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T04:14:33Z","timestamp":1731989673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673624017744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":37,"journal-issue":{"issue":"10466","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0140673624017744"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(24)01774-4","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(24)01774-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(24)02138-X","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}